A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

NCT02624167

PHASE2INTERVENTIONAL

Newron Pharmaceuticals SPA

90 participants

Started 2015-12 · Completed 2017-01

Status: Completed (as of 12-23-2025)

Conditions

Chronic Schizophrenia

Interventions

DRUG: NW-3509A DRUG: Placebo

Linked Papers (from SciSciNet-V2)

Total Papers15

Background

2

Result

0

Derived

0

Unknown

13

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in patients with chronic schizophrenia that are not responding adequately to their current antipsychotic medication (aripiprazole or risperidone). NW-3509A is given as an oral dose range of 15 to 25 mg, BID in a 1:1 ratio.

Sort by:

Background Papers4

Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA’s Pediatric Suicidal Risk Analysis of Antidepressants

Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA’s Pediatric Suicidal Risk Analysis of Antidepressants

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers13

The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

33,264 citations

The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

19,723 citations

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

5,799 citations

Assessing Depression in Schizophrenia: The Calgary Depression Scale

1,068 citations

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

Prediction of Outcome in Schizophrenia

Manual for the Extrapyramidal Symptom Rating Scale (ESRS)

Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia

The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

Polymorphism in <scp>CYP</scp>2D6 and <scp>CYP</scp>2C19, members of the cytochrome P450 mixed‐function oxidase system, in the metabolism of psychotropic drugs

Schizophrenia and valproate.

Voltage-Gated Sodium Channels in Neurological Disorders